Evidence map›Paper›PMID 41263395›Full record

ArticleCancer medicine2025

An Integrated Clinical-Radiomics-Deep Learning Model Based on

Yun Wang, Zhaoqing Chen, Jing Li, Yuhuang Cai, Chengyang Sun, Jingjing Zhang, Marcus Hacker, Xiang Li, Heqing Yi

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yun WangDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Zhaoqing ChenSchool of Information Engineering and Internet of Things, Huzhou Vocational Technical College, Huzhou, Zhejiang, China.
Jing LiDepartment of Nuclear Medicine, Aksu Prefecture First People's Hospital, Aksu, Xinjiang, China.
Yuhuang CaiPostgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Chengyang SunPostgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Jingjing ZhangPostgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Wien, Austria.
Xiang LiDepartment of Nuclear Medicine, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Heqing YiDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-5164-4821

Funding

Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission 2022PY043Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission 2023KY068Zhejiang Province Natural Science Foundation of China LTGY24H180013
6 · The paper itself

Abstract

backgroundAn integrated model combining clinical variables, radiomic features, and deep learning was developed to predict EGFR mutation status in patients with lung adenocarcinoma based on pretreatment

methodsIn this retrospective study, data from 218 patients-including PET/CT images, EGFR mutation status, and clinical characteristics-were analyzed. Three predictive models were constructed: a clinical model (C), a clinical-radiomics model (CR), and a clinical-radiomics-deep learning model (CRD).

resultsThe CRD model integrated screened clinical features, as well as ConvNext-based deep learning scores and radiomic scores selected via LASSO regression. It exhibited significantly superior predictive performance to the C model (AUC = 0.599; DeLong test: Z = -3.522, p < 0.001, corrected p = 0.001) and the CR model (AUC = 0.739; DeLong test: Z = -2.197, p = 0.028, corrected p = 0.028), with an AUC of 0.821 for the CRD model. Calibration curves and decision curve analysis confirmed its robustness and potential clinical benefit. A nomogram based on the CRD model was established, enabling individualized risk prediction of EGFR mutation.

conclusionsThis study highlights the potential of integrating clinical, radiomic, and deep learning features as a noninvasive approach for accurately predicting EGFR mutation status in lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungDeep LearningLung NeoplasmsMutationPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overErbB ReceptorsFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedRadiomicsRadiopharmaceuticalsEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18Radiopharmaceuticals18F‐FDG PET/CTdeep learningepidermal growth factor receptorlung adenocarcinoma

Identifiers

PMID41263395
PMCPMC12631541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.